EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Awareness of and Adherence to the Pregnancy Prevention Program for Oral Retinoids: A Questionnaire Survey in Denmark

Dana Backran, Sophia Ahmad, Johanne M Hansen iD, Anna Birna Almarsdóttir iD, Ramune Jacobsen iD

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.70023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Dana Backran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Retinoids, Health Knowledge, Attitudes, Practice. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

We aimed to investigate the awareness of oral retinoid teratogenicity and the adherence to the pregnancy prevention program (PPP) related to oral retinoid use by physicians, pharmacists, and patients in Denmark.

Methods

As part of the multi‐country survey, web‐based questionnaires were distributed among Danish dermatologists, general practitioners, community pharmacists, and women of childbearing age, who were using or had used oral retinoids within the past 5 years.

Results

A total of 62 physicians, 96 pharmacists, and 50 oral retinoid using women responded; 95%, 100%, and 98%, respectively, were aware of the teratogenic risks of oral retinoids. For physicians, the most applied PPP measures were the usage of the patient (44%) and the healthcare professional (19%) guides, while the least applied measure was signing medication risk awareness form (3%). Among the pharmacists, the warning sign on the outer medication package was the most used measure (45%). Among the women, a majority (90%) had read the patient information leaflet included in the medication package and 72% discussed the use of contraception with their healthcare provider, while risk awareness forms and patient cards were seen by only few.

Conclusions

In Denmark, physicians, pharmacists, and medicine users were aware about the teratogenic effects of oral retinoids. Adherence to pregnancy prevention measures varied, suggesting unwillingness to use the measures that require patients' signatures among physicians and a lack of awareness of pharmacy targeting measures. Accessibility of the latter measures need to be optimized to improve the safety of oral retinoid use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinoidsHealth Knowledge, Attitudes, PracticeHumansFemaleDenmarkPregnancySurveys and QuestionnairesAdultAdministration, OralAbnormalities, Drug-InducedMalePharmacistsTeratogensYoung AdultMiddle AgedPhysiciansDrug Monitoring

Stichwörter der Autor:innen

Denmarkhealthcare professionalsoral retinoidspatientspharmacistspregnancy preventionquestionnaires

Substanzen

RetinoidsTeratogens

Autor:innen und Institutionen

  • Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.

ORCID-Profile: Johanne M Hansen, Anna Birna Almarsdóttir, Ramune Jacobsen

Zitieren

APA

Backran, D., Ahmad, S., Hansen, J. M., Almarsdóttir, A. B., & Jacobsen, R. (2024). The Awareness of and Adherence to the Pregnancy Prevention Program for Oral Retinoids: A Questionnaire Survey in Denmark. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70023

Vancouver

Backran D, Ahmad S, Hansen JM, Almarsdóttir AB, Jacobsen R. The Awareness of and Adherence to the Pregnancy Prevention Program for Oral Retinoids: A Questionnaire Survey in Denmark. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70023

BibTeX
@article{Backran2024,
  author = {Backran, Dana and Ahmad, Sophia and Hansen, Johanne M and Almarsdóttir, Anna Birna and Jacobsen, Ramune},
  title = {The Awareness of and Adherence to the Pregnancy Prevention Program for Oral Retinoids: A Questionnaire Survey in Denmark},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.70023}
}
Kostenlos starten →